Amendment to Delete or Correct Basis

RETINOSTAT

Oxford BioMedica plc

Amendment to Delete or Correct Basis

Trademark Snap Shot Amendment to Delete or Correct Basis (Table presents the data on Amendment to Delete or Correct Basis)
OVERVIEW
SERIAL NUMBER	78260879	FILING DATE	06/11/2003
REG NUMBER	0000000	REG DATE	N/A
REGISTER	PRINCIPAL	MARK TYPE	TRADEMARK
INTL REG #	N/A	INTL REG DATE	N/A
TM ATTORNEY	BUTLER, MIDGE FAE	L.O. ASSIGNED	107

PUB INFORMATION
RUN DATE	12/20/2007
PUB DATE	04/10/2007
STATUS	690-NOTICE OF ALLOWANCE - CANCELLED
STATUS DATE	07/18/2007
LITERAL MARK ELEMENT	RETINOSTAT

DATE ABANDONED	N/A	DATE CANCELLED	N/A
SECTION 2F	NO	SECTION 2F IN PART	NO
SECTION 8	NO	SECTION 8 IN PART	NO
SECTION 15	NO	REPUB 12C	N/A
RENEWAL FILED	NO	RENEWAL DATE	N/A
DATE AMEND REG	N/A

FILING BASIS
FILED BASIS		CURRENT BASIS		AMENDED BASIS
1 (a)	NO	1 (a)	NO	1 (a)	NO
1 (b)	YES	1 (b)	NO	1 (b)	NO
44D	YES	44D	NO	44D	NO
44E	NO	44E	YES	44E	NO
66A	NO	66A	NO
NO BASIS	NO	NO BASIS	NO

MARK DATA
STANDARD CHARACTER MARK	NO
LITERAL MARK ELEMENT	RETINOSTAT
MARK DRAWING CODE	1-TYPESET WORD(S)/LETTER(S)/NUMBER(S)
COLOR DRAWING FLAG	NO

CURRENT OWNER INFORMATION
PARTY TYPE	20-OWNER AT PUBLICATION
NAME	Oxford BioMedica plc
ADDRESS	Medawar Centre Robert Robinson Avenue The Oxford Science Park Oxford, OX4 4GA
ENTITY	11-COMPANY
CITIZENSHIP	United Kingdom

GOODS AND SERVICES
INTERNATIONAL CLASS	001
DESCRIPTION TEXT	Chemical and biochemical products for use in gene delivery technology, namely, enzymes; chemical products for in-vitro use in laboratories and for analysis in gene delivery technology, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use in gene delivery technology

INTERNATIONAL CLASS	005
DESCRIPTION TEXT	Gene therapy and prophylaxis products, namely, gene delivery, gene transfer, gene regulation and gene modulation for the treatment of blood disorders, cancers, diseases of the nervous system, macular degeneration, diabetic retinopathy, diabetes, inflammatory and auto-immune diseases, vascular disorders, disorders arising from improper vascularisation and single gene disorders; pharmaceutical substances and preparations for use in the medical industry, namely vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations, all for use in gene delivery technologies, vector production technologies and neurogenomics products; chemical products for use in medical science, particularly for treatment of disease of the eye, vascular and neovascularisation disorders and retinopathy; pharmaceutical and biochemical preparations for the treatment of macular degeneration and retinopathy and angiogenesis; instruments and apparatus for the administration of gene and antibody-based therapy and prophylaxis preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes

INTERNATIONAL CLASS	042
DESCRIPTION TEXT	Scientific and medical research and development; engineering services, biotechnology services, namely, biotechnology research in the development of therapeutic and prophylactic products and vaccines; licensing of intellectual property; advisory services relating to the research and development of gene therapy; consultation services in the fields of medical and scientific research in the field of professional gene therapy; medical research and development in the field of vector production technologies

GOODS AND SERVICES CLASSIFICATION
INTERNATIONAL CLASS	001	FIRST USE DATE	NONE	FIRST USE IN COMMERCE DATE	NONE	CLASS STATUS	6-ACTIVE

INTERNATIONAL CLASS	005	FIRST USE DATE	NONE	FIRST USE IN COMMERCE DATE	NONE	CLASS STATUS	6-ACTIVE

INTERNATIONAL CLASS	042	FIRST USE DATE	NONE	FIRST USE IN COMMERCE DATE	NONE	CLASS STATUS	6-ACTIVE

MISCELLANEOUS INFORMATION/STATEMENTS
CHANGE IN REGISTRATION	NO

FOREIGN INFORMATION
PRIORITY CLAIMED	SEC. 44(D) ON Office for Harmonization in the Internal Market (Trade Marks and Designs) (OHIM)
APPLICATION NO.	003110764
APPLICATION FILING DATE	03/16/2003
FOREIGN REG NO.	003110764
FOREIGN REG DATE	07/03/2005
FOREIGN RNWL NUM	N/A
DATE OF FOREIGN RNWL	N/A
FOREIGN EXPIRATION	07/03/2015
FOREIGN RNWL EXPIRATION	N/A

PROSECUTION HISTORY
DATE	ENT CD	ENT TYPE	DESCRIPTION	ENT NUM
12/19/2007	DP1B	I	1(B) BASIS DELETED; PROCEED TO REGISTRATION	062
07/18/2007	IUCN	S	NOTICE OF ALLOWANCE CANCELLED	061
07/18/2007	D1BR	I	TEAS DELETE 1(B) BASIS RECEIVED	060
07/03/2007	NOAM	O	NOTICE OF ALLOWANCE-MAILED	059
04/10/2007	PUBO	A	PUBLISHED FOR OPPOSITION	058
03/21/2007	NPUB	O	NOTICE OF PUBLICATION	057
02/26/2007	PREV	O	LAW OFFICE PUBLICATION REVIEW COMPLETED	056
02/26/2007	ALIE	A	ASSIGNED TO LIE	055
01/22/2007	CNSA	P	APPROVED FOR PUB - PRINCIPAL REGISTER	054
01/19/2007	TEME	I	TEAS/EMAIL CORRESPONDENCE ENTERED	053
01/18/2007	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	052
01/18/2007	TROA	I	TEAS RESPONSE TO OFFICE ACTION RECEIVED	051
07/21/2006	CNRT	O	NON-FINAL ACTION MAILED	050
07/20/2006	CNRT	R	NON-FINAL ACTION WRITTEN	049
07/20/2006	DOCK	D	ASSIGNED TO EXAMINER	048
07/13/2006	ZZZX	Z	PREVIOUS ALLOWANCE COUNT WITHDRAWN	047
07/13/2006	TEME	I	TEAS/EMAIL CORRESPONDENCE ENTERED	046
07/11/2006	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	045
07/11/2006	TROA	I	TEAS RESPONSE TO OFFICE ACTION RECEIVED	044
06/02/2006	PBCR	Z	WITHDRAWN FROM PUB - OG REVIEW QUERY	043
05/12/2006	PREV	O	LAW OFFICE PUBLICATION REVIEW COMPLETED	042
05/05/2006	ALIE	A	ASSIGNED TO LIE	041
05/01/2006	CNSA	P	APPROVED FOR PUB - PRINCIPAL REGISTER	040
04/27/2006	TEME	I	TEAS/EMAIL CORRESPONDENCE ENTERED	039
04/20/2006	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	038
04/21/2006	TROA	I	TEAS RESPONSE TO OFFICE ACTION RECEIVED	037
04/20/2006	TROA	I	TEAS RESPONSE TO OFFICE ACTION RECEIVED	036
02/28/2006	CNRT	O	NON-FINAL ACTION MAILED	035
02/28/2006	CNRT	R	NON-FINAL ACTION WRITTEN	034
02/21/2006	ZZZX	Z	PREVIOUS ALLOWANCE COUNT WITHDRAWN	033
02/09/2006	PBCR	Z	WITHDRAWN FROM PUB - OG REVIEW QUERY	032
01/20/2006	PREV	O	LAW OFFICE PUBLICATION REVIEW COMPLETED	031
01/13/2006	ALIE	A	ASSIGNED TO LIE	030
01/09/2006	CNSA	P	APPROVED FOR PUB - PRINCIPAL REGISTER	029
01/07/2006	TEME	I	TEAS/EMAIL CORRESPONDENCE ENTERED	028
01/04/2006	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	027
01/04/2006	TROA	I	TEAS RESPONSE TO OFFICE ACTION RECEIVED	026
10/26/2005	CRML	O	CORRESPONDENCE MAILED	025
10/26/2005	CPRA	R	PRIORITY ACTION WRITTEN	024
10/03/2005	ACEC	I	AMENDMENT FROM APPLICANT ENTERED	023
09/19/2005	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	022
09/19/2005	MAIL	I	PAPER RECEIVED	021
08/04/2005	CNSL	S	LETTER OF SUSPENSION MAILED	020
08/04/2005	CNSL	R	SUSPENSION LETTER WRITTEN	019
08/03/2005	ACEC	I	AMENDMENT FROM APPLICANT ENTERED	018
07/22/2005	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	017
07/22/2005	MAIL	I	PAPER RECEIVED	016
01/31/2005	FAXX	O	FAX SENT	015
01/28/2005	TCCA	I	TEAS CHANGE OF CORRESPONDENCE RECEIVED	014
01/19/2005	GNSI	S	INQUIRY TO SUSPENSION E-MAILED	013
01/19/2005	CNSI	R	SUSPENSION INQUIRY WRITTEN	012
07/19/2004	GNSL	S	LETTER OF SUSPENSION E-MAILED	011
06/21/2004	TEME	I	TEAS/EMAIL CORRESPONDENCE ENTERED	010
06/21/2004	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	009
06/21/2004	ACEC	I	AMENDMENT FROM APPLICANT ENTERED	008
06/21/2004	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	007
06/21/2004	TROA	I	TEAS RESPONSE TO OFFICE ACTION RECEIVED	006
12/22/2003	GNRT	F	NON-FINAL ACTION E-MAILED	005
12/18/2003	DOCK	D	ASSIGNED TO EXAMINER	004
07/02/2003	AMPX	O	APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED	003
07/02/2003	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	002
07/02/2003	PARI	I	TEAS PRELIMINARY AMENDMENT RECEIVED	001

CURRENT CORRESPONDENCE INFORMATION
ATTORNEY	CHRISTOPHER J SCHULTE
CORRESPONDENCE ADDRESS	CHRISTOPHER J SCHULTE MERCHANT & GOULD PO BOX 2910 MINNEAPOLIS, MN 55402-0910
DOMESTIC REPRESENTATIVE	NONE

PRIOR OWNER INFORMATION
PARTY TYPE	10-ORIGINAL APPLICANT
NAME	Oxford BioMedica plc
ADDRESS	Medawar Centre Robert Robinson Avenue The Oxford Science Park Oxford, OX4 4GA
ENTITY	11-COMPANY
CITIZENSHIP	United Kingdom